share_log

Raymond James Maintains Strong Buy on VBI Vaccines, Lowers Price Target to $5

Benzinga Real-time News ·  Aug 9, 2022 08:24

Raymond James analyst Steven Seedhouse maintains VBI Vaccines (NASDAQ:VBIV) with a Strong Buy and lowers the price target from $6 to $5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment